Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab Randomized Withdrawal Extension Study in Hidradenitis Suppurativa
jRCT2080225212Phase 3Completed
- Sponsor
- Novartis
- Start
- May 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in hidradenitis suppurativa (HS) comparing Secukinumab maintenance with Placebo withdrawal (2 arms). Started May 2020; status: completed.
02
Drugs
secukinumab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on jRCT2080225212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225212.